These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 28583367)

  • 41. Cancer-Targeted Nanotheranostics: Recent Advances and Perspectives.
    Ma Y; Huang J; Song S; Chen H; Zhang Z
    Small; 2016 Sep; 12(36):4936-4954. PubMed ID: 27150247
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent advances in nanomaterials for neural applications: opportunities and challenges.
    Sisubalan N; Shalini R; Ramya S; Sivamaruthi BS; Chaiyasut C
    Nanomedicine (Lond); 2023 Nov; 18(26):1979-1994. PubMed ID: 38078433
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two-Dimensional Nanomaterials for Cancer Nanotheranostics.
    Chen Y; Wu Y; Sun B; Liu S; Liu H
    Small; 2017 Mar; 13(10):. PubMed ID: 28075057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Importance of Theranostics in Rare Brain-Eating Amoebae Infections.
    Anwar A; Siddiqui R; Khan NA
    ACS Chem Neurosci; 2019 Jan; 10(1):6-12. PubMed ID: 30149693
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Upconversion nanotheranostics: emerging designs for integration of diagnosis and therapy.
    Muthu MS; Mehata AK; Viswanadh MK
    Nanomedicine (Lond); 2017 Mar; 12(6):577-580. PubMed ID: 28244815
    [No Abstract]   [Full Text] [Related]  

  • 46. Advances in nanomedicines for diagnosis of central nervous system disorders.
    Zhang X; Zhou J; Gu Z; Zhang H; Gong Q; Luo K
    Biomaterials; 2021 Feb; 269():120492. PubMed ID: 33153757
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nano-enabled delivery systems across the blood-brain barrier.
    Hwang SR; Kim K
    Arch Pharm Res; 2014 Jan; 37(1):24-30. PubMed ID: 24170511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Theranostic potential of graphene quantum dots for multiple sclerosis.
    Demirdöğen BC
    Mult Scler Relat Disord; 2022 Dec; 68():104232. PubMed ID: 36244187
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Green Synthesized Nanomaterials as Theranostic Platforms for Cancer Treatment: Principles, Challenges and the Road Ahead.
    Rajasekharreddy P; Huang C; Busi S; Rajkumari J; Tai MH; Liu G
    Curr Med Chem; 2019; 26(8):1311-1327. PubMed ID: 28294042
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.
    Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
    CNS Neurol Disord Drug Targets; 2016; 15(9):1079-1091. PubMed ID: 27633786
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy.
    Piktel E; Niemirowicz K; Wątek M; Wollny T; Deptuła P; Bucki R
    J Nanobiotechnology; 2016 May; 14(1):39. PubMed ID: 27229857
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Strategies for transporting nanoparticles across the blood-brain barrier.
    Zhang TT; Li W; Meng G; Wang P; Liao W
    Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modernistic and Emerging Developments of Nanotechnology in Glioblastoma-Targeted Theranostic Applications.
    Lakshmi BA; Kim YJ
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163563
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Magnetic hybrid nanovesicles for the precise diagnosis and treatment of central nervous system disorders.
    Salatin S; Farhoudi M; Sadigh-Eteghad S; Mahmoudi J
    Expert Opin Drug Deliv; 2024 Apr; 21(4):521-535. PubMed ID: 38555483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nanotheranostics: advanced nanomedicine for the integration of diagnosis and therapy.
    Muthu MS; Mei L; Feng SS
    Nanomedicine (Lond); 2014 Jul; 9(9):1277-80. PubMed ID: 25204816
    [No Abstract]   [Full Text] [Related]  

  • 56. Theranostic Applications of Nanomaterials in Alzheimer's Disease: A Multifunctional Approach.
    Tripathi P; Shukla P; Bieberich E
    Curr Pharm Des; 2022; 28(2):116-132. PubMed ID: 34809540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanotechnology-novel therapeutics for CNS disorders.
    Srikanth M; Kessler JA
    Nat Rev Neurol; 2012 Apr; 8(6):307-18. PubMed ID: 22526003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nano-embedded medical devices and delivery systems in interventional radiology.
    San Valentin EMD; Barcena AJR; Klusman C; Martin B; Melancon MP
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Jan; 15(1):e1841. PubMed ID: 35946543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.
    Guo ZH; Khattak S; Rauf MA; Ansari MA; Alomary MN; Razak S; Yang CY; Wu DD; Ji XY
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting.
    Muldoon LL; Tratnyek PG; Jacobs PM; Doolittle ND; Christoforidis GA; Frank JA; Lindau M; Lockman PR; Manninger SP; Qiang Y; Spence AM; Stupp SI; Zhang M; Neuwelt EA
    AJNR Am J Neuroradiol; 2006 Mar; 27(3):715-21. PubMed ID: 16552023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.